Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-10
ICR Author
Marsden,
Author
Seddon, B
Strauss, SJ
Whelan, J
Leahy, M
Woll, PJ
Cowie, F
Rothermundt, C
Wood, Z
Benson, C
Ali, N
Marples, M
Veal, GJ
Jamieson, D
Küver, K
Tirabosco, R
Forsyth, S
Nash, S
Dehbi, H-M
Beare, S
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/1450
DOI
https://doi.org/10.1016/s1470-2045(17)30622-8
Collections
  • Other ICR Research
Language
eng
License start date
2017-10
Citation
The Lancet Oncology, 2017, 18 (10), pp. 1397 - 1410
Publisher
Elsevier BV

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.